Therefore, we hypothesized that vaccinating mice with Ad-T34A-mSurvivin followed by MG1-T34A-mSurvivin would induce potent survivin-specific T cell responses that could then be evaluated for efficacy in multiple murine cancer models. Here, BIRC5 is linked to cancer.